Australia's inflation rate recently reached 4%, and the Reserve Bank lifted its cash rate target to 4.60%, partly linked to the artificial intelligence boom. Higher funding costs can pressure many sectors. Healthcare groups using AI to improve diagnoses, tailor treatments and run hospitals more efficiently could still attract attention. This article highlights three Australian AI healthcare stocks from our focused screener that investors may want on their watchlist.
The three stocks below are just a sample drawn from this theme, and the full screen surfaced 4 more Australian AI healthcare companies with similarly compelling stories that are not covered in this article. To go deeper on this idea, identify potential outliers, and pressure test your own watchlist, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener
ImExHS (ASX:IME)
ImExHS uses cloud-based imaging platforms to feed data into AI tools for radiology, pathology and cardiology, while also running a sizeable teleradiology service. This gives this screener a pure view of how AI-ready workflows can scale inside real hospital settings.
ImExHS generates about A$10 million from software and A$21 million from radiology services, reflecting a business still weighted to service income, and the stock's market cap is around A$18 million.
"The quarterly release indiates the company is getting through to profitability and cashflow sustainability. They also understand the challenge now is to drive the software sales and revenue much faster in 2026."
What happens when one quiet shift in how those imaging contracts are structured starts to affect both pricing power and margins at scale?
If that contract shift is what matters most for margins at ImExHS, the full narrative for ImExHS explains how software mix, pricing and execution could accelerate or stall outcomes.
Singular Health Group (ASX:SHG)
Singular Health Group builds 3DICOM, a volumetric rendering platform that turns CT, MRI and PET scans into 3D models and runs AI in the Cloud to support image analysis. The business generated about A$1.9 million from 3D medical software and has a market cap near A$60 million.
Singular Health Group aligns tightly with the AI healthcare theme because its 3DICOM platform uses cloud based models to help clinicians interpret scans faster and more accurately, even though revenue is still small and losses are significant. Investors watching AI imaging may focus on how quickly that early traction converts into something larger if a single pressure point on commercial adoption shifts.
If that tipping point on commercial adoption is what you care about, the analysis report for Singular Health Group shows where Singular Health Group could surprise if momentum improves.
Artrya (ASX:AYA)
Artrya sits squarely in the AI imaging camp, using its Salix software to read coronary CT angiography scans and support earlier heart disease decisions. This positioning puts the business right in the middle of how AI could change hospital diagnostics and cardiology workflows.
Artrya develops Salix, an AI platform that reads coronary CT angiography scans to flag coronary artery disease, and currently records about A$0.03 million in revenue from this technology in Australia, with a market cap near A$603 million.
"Growing adoption of CCTA as a front-line tool for chest pain assessment, together with up to 400,000 scans a year across SAPPHIRE partners at a blended rate of about US$850 per scan across three modules, gives Artrya a clear volume pathway that directly targets future subscription and fee per scan revenue."
What happens if one unseen constraint on real world AI imaging uptake shifts just enough to change the slope of that revenue curve?
If that constraint is starting to ease, the full narrative for Artrya outlines how Artrya's coronary focus could accelerate, stall or be quietly reshaped by hospital level adoption risks.
Seeking Alternatives Before Everyone Else?
Fresh themes move fast, and once momentum builds the best entry points get caught in the rush. Scan curated ideas under the radar for now and consider acting before conditions change.
-
Spot potential income anchors while yields are still flying under most radars by running your filters through the 3 dividend fortresses .
-
Track where capital is quietly gathering before the crowd by checking the hand picked 7 resilient stocks with low risk scores .
-
Position ahead of potential infrastructure opportunities by reviewing the curated 40 power grid technology and infrastructure stocks .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
